恩替卡韦治疗代偿期乙型肝炎肝硬化的疗效与安全性观察

目的观察恩替卡韦治疗代偿期乙型肝炎肝硬化患者的疗效与安全性。方法 60例乙型肝炎肝硬化代偿期患者接受恩替卡韦治疗72周,观察患者生化学指标、病毒学指标和组织学指标的变化情况。结果所有患者均没有发展到失代偿期,生化学指标、病毒学指标和组织学指标均有明显改善,差异有统计学意义(P<0.05)。结论代偿期乙型肝炎肝硬化患者选用恩替卡韦有良好的疗效及安全性。

Clinical observation on compensated cirrhosis patients following chronic hepatitis B virus infection treated with entecavir

Objective To determine the clinical therapeutic effect and security of entecavir on compensated cirrhosis patients following chronic hepatitis.Methods Sixty cases of hepatitis B patients with cirrhosis were received entecavir for 72 weeks.Observe the biochemical indicators,virological indicators,histological indicators.Results After anti-viral treatment for 72 weeks,no patients developed into decompensated state,biochemical indicators,virological indicators,and histological indicators had all improved,the differences were statistically significant.Conclusion Treatment of entecavir on hepatitis B patients with cirrhosis was safe and effected.